876761-25-0

Basic information

• Product Name: 4-tert-butoxycarbonylamino-4-cyclohexyl-butyric acid
• Synonyms: 4-tert-butoxycarbonylamino-4-cyclohexyl-butyric acid
• CAS NO: 876761-25-0
• Molecular Weight: 285.384
• Mol File: 876761-25-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-tert-butoxycarbonylamino-4-cyclohexyl-butyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-tert-butoxycarbonylamino-4-cyclohexyl-butyric acid(876761-25-0)
• EPA Substance Registry System: 4-tert-butoxycarbonylamino-4-cyclohexyl-butyric acid(876761-25-0)

Safety Data

• Hazardous Substances Data: 876761-25-0(Hazardous Substances Data)

Upstream product

• 876761-54-5 (S)-4-tert-butoxycarbonylamino-4-cyclohexyl-butyric acid methyl ester 
• 77-92-9 citric acid 
• 876761-24-9 C₁₇H₂₉NO₄ 
• 171560-20-6 (2R)-2-(1,1-dimethylethoxycarbonylamino)-2-cyclohexylethanal 
• 188348-02-9 tert-butyl (R)-(methoxycarbonyl)(cyclohexyl)methylcarbamate 
• 70491-05-3 (2R)-[(tert-butoxycarbonyl)-amino](cyclohexyl)ethanoic acid 

Downstream Products

• 876761-29-4 4-(2-amino-5-phenoxy-benzylamino)-4,N-dicyclohexyl-N-methyl-butyramide 
• 877032-57-0 4-(2-amino-6-phenoxy-4H-quinazolin-3-yl)-4-(S)-,N-dicyclohexyl-N-methyl-butyramide 
• 1397458-19-3 C₃₆H₄₇N₅O₂S 
• 1397458-21-7 C₃₆H₄₇N₅O₂S 
• 1397458-23-9 C₃₇H₄₉N₅O₂S 
• 1397458-25-1 C₃₆H₄₇N₅O₃S 
• 1397458-27-3 C₃₅H₄₆N₆O₂ 

Relevant articles and documents

Synthesis, radiolabeling, and evaluation of a potent β-site APP cleaving enzyme (BACE1) inhibitor for PET imaging of BACE1 in vivo

The β-site APP-cleaving enzyme 1 (BACE1) plays important roles in the proteolytic processing of amyloid precursor protein, and can be regarded as an important target for the diagnosis and treatment of AD. This study aimed to report the synthesis and evaluation of an 18F-labeled 2-amino-3,4-dihydroquinazoline analog as a potential BACE1 radioligand. A fluoropropyl side chain was introduced to the phenyl of this 3,4-dihydroquinazoline scaffold to generate the radioligand. Our preliminary data indicated that although the 2-amino-3,4-dihydroquinazoline scaffold possessed favorable in-vitro properties as a PET ligand, its poor brain uptake hindered the in-vivo imaging of BACE1. Further investigation would be required to optimize the scaffold for the development of a blood-brain-barrier-permeable BACE1-targeted PET ligand.

SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE

The present invention relates to substituted amino-benzimidazoles of general formula (1) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE)

The present invention is directed to macrocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.